Riskpilot← Back to searchSign inGet full accessAGB-Pharma AB
ABActiveOrg 5568592074LundManufacture of pharmaceutical preparations · NACE 2120Est. 201110-19 employees
Revenue 2024
SEK 194,8M
-23% vs 2023
EBITDA margin
1.2%
-97% vs 2023
Equity ratio
43.2%
Financial strength
Net profit 2024
SEK 4,7M
-93% vs 2023
| Revenue | SEK 194,8M | -23% |
| EBITDA | SEK 2,4M | -97% |
| Net profit | SEK 4,7M | -93% |
| Total assets | SEK 96,3M | -48% |
| Equity | SEK 41,6M | -57% |
| Employees | — | — |
Legal name
AGB-Pharma AB
Org number
5568592074
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
11 juli 2011
Share capital
SEK 50 000
Employees
10-19
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av Henningsson, Stig Sven Gunnar Henningsson, Ulla Anne-Charlotte Firman tecknas av en av ledamöterna i förening med externa firmatecknaren
Company purpose
Bolagets verksamhet är att äga och förvalta aktier och övriga finansiella instrument. Bolaget ska bedriva försäljning av läkemedel, och annan därmed förenlig verksamhet. Konsultverksamhet inom ovan nämnda områden. Bolaget skall dessutom förvalta fast egendom samt därmed förenlig verksamhet.
Address
Lund
Email
fredrik.werner@agb-pharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 166 530 | 242 244 | 253 301 | 194 839 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −19 406 | 46 825 | 122 476 | 81 243 | 2 427 |
| Depreciation & amort. | −9 | −720 | −721 | −728 | −734 |
| EBIT | −19 415 | 46 105 | 121 755 | 80 515 | 1 693 |
| Net financials | 98 996 | −1 | 2 116 | 2 947 | 3 605 |
| Profit before tax | 79 581 | 38 368 | 123 180 | 92 606 | 5 787 |
| Tax | −0 | −3 540 | −25 018 | −19 882 | −1 055 |
| Net profit | 79 581 | 34 828 | 98 162 | 72 724 | 4 732 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 92 700 | 147 319 | 178 869 | 184 924 | 96 273 |
| Equity | 81 170 | 115 998 | 114 160 | 96 884 | 41 615 |
| Long-term debt | 569 | 569 | 497 | 497 | 497 |
| Short-term debt | 10 380 | 21 553 | 53 683 | 81 269 | 46 057 |
| Total debt | 10 949 | 22 122 | 54 180 | 81 766 | 46 554 |
EBITDA margin
1.2%
This company
15.8%
Market median
-92% vs market
20202024
Equity ratio
43.2%
This company
38.2%
Market median
+13% vs market
20202024
Return on equity
11.4%
This company
18.4%
Market median
+38% vs market
20202024
Net profit margin
2.4%
This company
8.1%
Market median
-70% vs market
20202024
Asset turnover
2.02×
This company
1.12×
Market median
+80% vs market
20202024
Debt / equity
1.31×
This company
0.62×
Market median
-111% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
KE External Signatory | External Signatory | 2024 |
CA | Audit | 2021 |
| Former (1) | ||
BF Chief Executive Officer | Chief Executive Officer | 2020 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2021 | |
| Board of Directors | 2019 | |
| Chairman | 2021 | |
| Former (1) | ||
| Deputy Board Member | 2021 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
S Development AB
AGB-Pharma AB Board members of AGB-Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karin Elisabeth Ruth Hesselgard | External Signatory | 0 companies |
| Björn Fredrik Lindberg | Chief Executive Officer | 0 companies |
| Curt Arne Jesper Ahlkvist | Audit | 0 companies |
| Ulla Anne-Charlotte Henningsson | Board of Directors | 0 companies |
| Emilie Helena Tammelin | Deputy Board Member | 0 companies |
| Stig Sven Gunnar Henningsson | Board of Directors | 0 companies |
| Nils Pontus Larsson Bergman | Chairman | 0 companies |